Biocon Expansion: The biosimilar to Johnson & Johnson's Stelara will be commercialised in nine additional markets, expanding Biocon's global reach in immunology. Biocon Limited has signed a licence agreement with Janssen Sciences Ireland that clears the way to commercialise Yesintek, its proposed biosimilar to Stelara (ustekinumab), in nine additional markets with immediate effect, the company told the stock exchanges on Monday.